NF-κB c-Rel Is a Potential Therapeutic Target for Acute Corneal Transplant Rejection.


Journal

Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701

Informations de publication

Date de publication:
01 Nov 2023
Historique:
medline: 15 11 2023
pubmed: 14 11 2023
entrez: 14 11 2023
Statut: ppublish

Résumé

The purpose of this study was to determine the role of nuclear factor kappa B (NF-κB) c-Rel during acute corneal transplant rejection and whether targeting c-Rel can reduce corneal transplant rejection. Allogeneic corneal transplantation was performed in wild-type and c-Rel-deficient mice. Corneal graft survival rate, opacity, neovascularization, and edema were evaluated by slit-lamp microscopy. Adeno-associated virus 6 (AAV6) expressing c-Rel-specific small hairpin RNA (AAV6-shRel) and the small-molecule compound pentoxifylline (PTXF) were used to reduce c-Rel expression. Enzyme-linked immunosorbent assay was used to determine the expression of inflammatory cytokines. c-Rel expression was determined by quantitative RT-PCR and western blot. The effect of c-Rel inhibition on corneal transplant rejection was examined using a mouse model of acute allogeneic corneal transplantation. Tear production and corneal sensitivity were measured to determine the potential toxicity of AAV6-shRel and PTXF. The expression of c-Rel and its inflammatory targets was increased in both mice and patients with corneal transplant rejection. Loss of c-Rel reduced corneal transplant rejection in mouse. Both AAV6-shRel and PTXF were able to downregulate the expression of c-Rel and its inflammatory targets in vitro. Treatment with AAV6-shRel or PTXF reduced corneal transplant rejection in mouse and downregulated the expression of inflammatory cytokines in peripheral blood mononuclear cells from patients with corneal transplant rejection. Treatment with AAV6-shRel or PTXF displayed no side effects on tear production or corneal sensitivity. Increased expression of c-Rel is a risk factor for acute corneal transplant rejection, and targeting c-Rel can efficiently reduce corneal transplant rejection.

Identifiants

pubmed: 37962530
pii: 2793011
doi: 10.1167/iovs.64.14.16
pmc: PMC10653260
doi:

Substances chimiques

NF-kappa B 0
Cytokines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

16

Références

Am J Transplant. 2021 Dec;21(12):3858-3870
pubmed: 34254428
J Exp Med. 2011 Oct 24;208(11):2321-33
pubmed: 22006976
Cell. 2017 Sep 7;170(6):1096-1108.e13
pubmed: 28886380
Immunol Cell Biol. 2017 Aug;95(7):593-600
pubmed: 28202908
Clin Immunol. 2016 Apr;165:47-54
pubmed: 26993753
Curr Opin Ophthalmol. 2013 Jul;24(4):329-35
pubmed: 23680758
Immunol Cell Biol. 2011 Jan;89(1):27-32
pubmed: 20975733
PLoS Pathog. 2011 Jan 20;7(1):e1001259
pubmed: 21283787
Transplantation. 2019 Dec;103(12):2468-2478
pubmed: 31765363
Circ J. 2002 May;66(5):499-504
pubmed: 12030348
Transplantation. 2000 Mar 15;69(5):1008-13
pubmed: 10755569
Arthritis Res Ther. 2008;10(5):R122
pubmed: 18847496
Transpl Immunol. 2021 Feb;64:101353
pubmed: 33238187
Curr Opin Ophthalmol. 2021 Jul 1;32(4):331-337
pubmed: 33989234
J Clin Med. 2020 Apr 28;9(5):
pubmed: 32354200
Immunol Invest. 2014;43(8):888-901
pubmed: 25296240
Invest Ophthalmol Vis Sci. 2002 Mar;43(3):639-46
pubmed: 11867578
Arch Immunol Ther Exp (Warsz). 2021 Nov 6;69(1):32
pubmed: 34741683
Int Immunopharmacol. 2018 Mar;56:9-17
pubmed: 29324391
Ocul Surf. 2005 Oct;3(4 Suppl):S165-8
pubmed: 17216111
Arch Ophthalmol. 1992 Oct;110(10):1392-403
pubmed: 1417537
J Clin Med. 2020 Feb 21;9(2):
pubmed: 32098130
Cell Immunol. 2002 May-Jun;217(1-2):47-57
pubmed: 12426000
J Vis Exp. 2014 Nov 17;(93):e51830
pubmed: 25490741
Neurochem Res. 2012 Apr;37(4):722-31
pubmed: 22219126
Pharmaceutics. 2020 Aug 13;12(8):
pubmed: 32823625
J Ophthalmic Vis Res. 2017 Jan-Mar;12(1):81-92
pubmed: 28299010
Ophthalmology. 1998 Oct;105(10):1855-65
pubmed: 9787355
Br J Ophthalmol. 2002 Sep;86(9):988-92
pubmed: 12185123
J Immunol. 2016 May 15;196(10):3983-91
pubmed: 27183635
Expert Opin Pharmacother. 2012 Apr;13(6):829-40
pubmed: 22424532
J Immunol. 2007 Jan 1;178(1):186-91
pubmed: 17182554
Mol Ther Methods Clin Dev. 2021 Sep 10;23:198-209
pubmed: 34703842
Int J Mol Sci. 2022 Mar 23;23(7):
pubmed: 35408825
Nucleic Acid Ther. 2018 Aug;28(4):209-224
pubmed: 29584585
Invest Ophthalmol Vis Sci. 1984 May;25(5):519-24
pubmed: 6370904
Int Ophthalmol Clin. 2009 Winter;49(1):31-41
pubmed: 19125062
Mol Ther Oncolytics. 2019 Oct 07;15:166-177
pubmed: 31720373
Mol Vis. 2005 Aug 29;11:632-40
pubmed: 16145544
Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1740-4
pubmed: 1542667
Immunity. 2009 Dec 18;31(6):932-40
pubmed: 20064450

Auteurs

Qian Zheng (Q)

Eye Institute of Shandong First Medical University, State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Qingdao, China.
Eye Institute of Shandong First Medical University, Eye Hospital of Shandong First Medical University (Shandong Eye Hospital), Jinan, China.

Ruiling Liu (R)

Eye Institute of Shandong First Medical University, State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Qingdao, China.

Bian Jiang (B)

Eye Institute of Shandong First Medical University, Qingdao Eye Hospital of Shandong First Medical University, Qingdao, China.

Jijun Sun (J)

Eye Institute of Shandong First Medical University, Eye Hospital of Shandong First Medical University (Shandong Eye Hospital), Jinan, China.

Ting Wang (T)

Eye Institute of Shandong First Medical University, Eye Hospital of Shandong First Medical University (Shandong Eye Hospital), Jinan, China.

Qingguo Ruan (Q)

Eye Institute of Shandong First Medical University, State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Qingdao, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH